Adherex Technologies Inc. (AHX) - Financial and Strategic SWOT Analysis Review


May 16, 2012
43 Pages - SKU: GBDT3903762
License type:
Adherex Technologies Inc. (AHX) - Financial and Strategic SWOT Analysis Review

Summary

Adherex Technologies Inc. (Adherex) discovers and develops novel cancer therapeutics focusing on tumor cells and tumor blood vessels and oncology. The company’s principle focus is on the development of Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, which it is developing to improve the tolerability and effectiveness of 5-fluorouracil (5-FU). Eniluracil is in Phase II trial for metastatic breast cancer. Adherex has three subsidiaries, but operates through, Adherex, Inc., as other subsidiaries are inactive. Adherex is headquartered in North Carolina, the US.

Adherex Technologies Inc. Key Recent Developments

May 11, 2012: Adherex Technologies Reports Q1 2012 Results
Nov 12, 2011: Adherex Technologies Reports Q3 2011 Results
Aug 11, 2011: Adherex Reports Financial Results For Q2 2011
May 13, 2011: Adherex Reports Net Income Of $4.7m For Q1 2011
Mar 31, 2011: Adherex Reports Net Loss Of $7.8m For Q4 2010

This comprehensive SWOT profile of Adherex Technologies Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.



More Pharmaceuticals Company reports by GlobalData

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2013 by GlobalData
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2013SummaryGlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 ...
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry by GlobalData
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical IndustrySummaryPharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform ...
Kuros Biosurgery AG - Product Pipeline Analysis, 2013 Update by GlobalData
SummaryKuros Biosurgery AG (Kuros) is a medical technology company.The company develops injectable biomaterial products for the trauma and wound care markets. It was formed as ...
OPKO Health, Inc. (OPK) - Product Pipeline Analysis, 2013 Update by GlobalData
SummaryOPKO Health, Inc. (OPKO), formerly eXegenics, Inc., is a US-based pharmaceutical and health care service provide. It operates in the diagnostics and pharmaceutical markets. The ...
See all reports like this >>